Adult Vitamin Injections Get Generic Green Light From FDA
Published Date: 11/17/2026
Notice
Summary
The FDA has decided that M.V.I. ADULT vitamins for injection weren’t taken off the market because they were unsafe or ineffective. This means drug companies can now apply to make generic versions of these vitamins, helping more people get access. No extra safety worries or delays—just a green light for more affordable options soon!
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
Green light to seek generics for M.V.I. ADULT
The FDA determined that M.V.I. ADULT (NDA 021625, initially approved January 30, 2004), a multivitamin injection indicated for prevention of vitamin deficiency in adults and pediatric patients aged 11 years and above receiving parenteral nutrition, was not withdrawn for reasons of safety or effectiveness. Because of that determination, drug companies may submit abbreviated new drug applications (ANDAs) that refer to this listed drug and FDA may approve those ANDAs if all other legal and regulatory requirements are met.
Possible labeling updates requested for ANDA applicants
The notice says that if FDA determines the labeling for M.V.I. ADULT should be revised to meet current standards, the Agency will advise ANDA applicants to submit such updated labeling. ANDA applicants that pursue approval for this product should be prepared to provide labeling conforming to any FDA guidance.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-23351, Rulemaking To Provide That N-acetyl-L-cysteine Is Not Excluded From the Dietary Supplement Definition
The FDA wants to officially say that N-acetyl-L-cysteine (NAC) can be sold as a dietary supplement. This means companies can legally put NAC in their products without breaking the rules, as long as they follow other laws. People and businesses making or selling supplements with NAC should share their thoughts by January 19, 2027.
2026-20848, Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods
The FDA is changing food rules to allow salt substitutes in many standardized foods, helping companies make lower-sodium options. This move aims to cut heart disease risks by reducing sodium without changing how foods basically taste or look. The new rule kicks in December 14, 2026, and food makers have until November 12, 2026, to raise any concerns, with no big costs expected.
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
Previous / Next Documents
Previous: 2026-23362, Combined Notice of Filings
The Federal Energy Regulatory Commission got new filings from natural gas pipeline companies about rate changes and agreements. These updates could affect pipeline customers and partners, with some changes starting as soon as November 1, 2026, and others in 2027. If you want to speak up, you’ve got until late November to file your comments or protests.
Next: 2026-23367, Determination That M.V.I. PEDIATRIC (Multiple Vitamins for Injection) Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The FDA has decided that M.V.I. PEDIATRIC vitamins for injection weren’t taken off the market because they’re unsafe or don’t work. This means drug companies can now apply to make generic versions of these vitamins, helping more kids get access to affordable options. If all rules are followed, these generics could hit the market soon, possibly saving money for families and healthcare providers.